Komori
Immuno-Biological Laboratories (4570) · InitiativeFirst stated

Development and sale of research reagents based on recombinant fibronectin

First written in FY2023. . Latest entry: FY2023.

1entries
1years
0from disclosures
Share on X
How it moved
Same theme, other companies
Commercialization and sales of recombinant fibronectin research reagentsA theme 1 companies write about · 0 as a headwind · 1 as a tailwind

No other company in this theme has enough history to compare yet.

Full recordFilings, disclosures and news, newest first
  1. FY2023First statedAnnual report

    「In this business, we developed production technologies for recombinant plasma fibronectin (Fibronectin Neosilk®, Plasma) and cellular fibronectin (Fibronectin Neosilk®, Cellular) using silkworms that do not carry human-infectious pathogens, and began selling them as research-use reagents on 13 March 2023.」

    Production technologies for plasma fibronectin and cellular fibronectin using genetically modified silkworms were developed, and sales as research-use reagents began on 13 March 2023.
Moved together

None of this company's other threads moved the same way in the same document twice or more.

When this could move next
No upcoming earnings preview for Immuno-Biological Laboratories yet.
News
No news is linked to this thread yet. When an article touches it, it will appear here by date.